Biogen Inc. (0R1B.L) LSE
185.53
-0.86(-0.46%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
185.53
-0.86(-0.46%)
Currency In USD
Address
225 Binney St
Cambridge, MA
United States of America (the)
Phone
17814642000
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
7605
First IPO Date
September 17, 1991
| Name | Title | Pay | Year Born |
| Christopher A. Viehbacher | President, Chief Executive Officer & Director | 6.15M | 1960 |
| Ginger Gregory | Executive VP & Chief Human Resources Officer | 1.59M | 1968 |
| Nicole Murphy | Executive VP and Head of Pharmaceutical Operations & Technology | 1.86M | 1973 |
| Priya Singhal | Executive VP & Head of Development | 1.95M | 1969 |
| Susan H. Alexander | Executive VP & Chief Legal Officer | 2.63M | 1957 |
| Adam Keeney | Executive VP & Head of Corporate Development | 0 | 1977 |
| Guy Hadari | Chief Information Officer | 0 | N/A |
| Sean Godbout | Chief Accounting Officer & Global Corporate Controller | 0 | N/A |
| Tim Power | Head of Investor Relations | 0 | N/A |
| Robin C. Kramer | Executive VP & CFO | 0 | 1966 |
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,800 full-time employees. The firm focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The firm markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). The company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The firm's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.